|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM180972413 |
| 003 |
DE-627 |
| 005 |
20250209151008.0 |
| 007 |
tu |
| 008 |
231223s2008 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0603.xml
|
| 035 |
|
|
|a (DE-627)NLM180972413
|
| 035 |
|
|
|a (NLM)18634442
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Tamaki, Masahiro
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Assessment of clinical usefulness of Eviprostat for benign prostatic hyperplasia--comparison of Eviprostat tablet with a formulation containing two-times more active ingredients
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.09.2008
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We compared the usefulness of Eviprostat tablet, a therapeutic agent for benign prostatic hyperplasia (BPH), and EVI-F tablet, a new formulation of Eviprostat containing two times more active ingredients (Chimaphila umbellata extract, Populus tremula extract, Pulsatilla pratensis extract, Equisetum arvense extract and purified wheat germ oil) and consequently designed to reduce the number of tablets per dose by half. In this study, patients with BPH were randomly assigned to either Eviprostat group (6 tabs/day) or EVI-F group (3 tabs/day) using the envelope method. The clinical efficacy of these two drugs were evaluated by the International Prostate Symptom Score (IPSS) and QOL score at the end of the treatment period, and their safety was evaluated by the incidence of side effects. Based on the clinical study guidelines for dysuria, the change in the IPSS total score and QOL score were comparable to the previously reported data for other treatment agents for BPH, and these indices showed gradual improvement with the treatment period. Both treatments were well tolerated. The clinical usefulness of the monotherapy with EVI-F tablet or Eviprostat tablet was reasonably demonstrated in this study. Furthermore, both treatments reduced nocturia, which has an impact on the QOL of patients with BPH
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a Plant Extracts
|2 NLM
|
| 650 |
|
7 |
|a Tablets
|2 NLM
|
| 650 |
|
7 |
|a Ethamsylate
|2 NLM
|
| 650 |
|
7 |
|a 24YL531VOH
|2 NLM
|
| 650 |
|
7 |
|a eviprostat
|2 NLM
|
| 650 |
|
7 |
|a 59738-67-9
|2 NLM
|
| 700 |
1 |
|
|a Nakashima, Masakazu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nishiyama, Ryuichi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ikeda, Hiroki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hiura, Masaru
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kanaoka, Toshio
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nakano, Tadasu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hayashi, Tadashi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ogawa, Osamu
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 54(2008), 6 vom: 07. Juni, Seite 435-45
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:54
|g year:2008
|g number:6
|g day:07
|g month:06
|g pages:435-45
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 54
|j 2008
|e 6
|b 07
|c 06
|h 435-45
|